(+)-Alpha-Dihydrotetrabenazine Phase I
Latest Information Update: 25 Aug 2017
Price :
$35 *
At a glance
- Drugs Dihydrotetrabenazine (Primary)
- Indications Neurological disorders
- Focus Pharmacokinetics
- 21 Aug 2017 Status changed from recruiting to completed.
- 24 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
- 24 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.